ArticleOpen medicine (Warsaw, Poland)2025
MZB1 regulates the immune microenvironment and inhibits ovarian cancer cell migration.
Article in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Role of MZB1 in disease pathogenesis: current insights and future directions.Clinical and experimental medicine · 2026Review
- Research progress on the role of MZB1 in immune regulation.Frontiers in immunology · 2026Review
- MZB1 at the ER-immunity interface: from antibody folding to disease vulnerability in autoimmunity, inflammation, and cancer.Journal of Cancer · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The immune microenvironment of ovarian cancer is crucial in its progression. Recent studies highlight the significant role of MZB1 in shaping the tumor immune microenvironment (TIME), although its specific function in ovarian cancer remains unclear. Materials and methods: We analyzed 381 ovarian cancer samples from the TCGA database, along with additional samples from GEO and single-cell datasets. Differentially expressed genes (DEGs) were identified using DESeq2. Various algorithms were applied to assess the relationship between MZB1 and the TIME. Cell proliferation was measured using the CCK-8 assay, while cell migration was evaluated using the wound healing assay. Furthermore, a nomogram predicting overall survival was developed based on multivariable Cox regression results. Results: Our results indicated a positive correlation between high MZB1 expression and improved clinical prognosis. Additionally, higher MZB1 expression was linked to increased immune cell infiltration within the TIME. Elevated MZB1 levels inhibited the migration and proliferation of SKOV3 cells. The nomogram's C-index was 0.702, and its calibration curve demonstrated good calibration, indicating satisfactory discrimination and accuracy in predicting patient outcomes. Conclusions: This study comprehensively analyzes MZB1's role in the TIME of ovarian cancer. MZB1 is a promising prognostic marker and a potential target for personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.